Journal of Medical Economics最新文献

{"title":"Cost effectiveness of implantable cardioverter defibrillators for 1.5 primary prevention of sudden cardiac arrest in China: an analysis from the Improve SCA study","authors":"Hui Sun, Xin Liu, Jin Fu, Yin Song, Xiaoxiao Qin, Haiyin Wang","doi":"10.1080/13696998.2024.2333187","DOIUrl":"https://doi.org/10.1080/13696998.2024.2333187","url":null,"abstract":"Implantable cardioverter defibrillator (ICDs) for primary prevention (PP) of sudden cardiac arrest (SCA) is underutilized in developing countries. The Improve SCA study has identified a subset of 1...","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":"48 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140564460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-effectiveness and impact on infections and associated antimicrobial resistance of 20-valent pneumococcal conjugate vaccine in US children previously immunized with PCV13","authors":"Mark H. Rozenbaum, Liping Huang, Alejandro Cane, Adriano Arguedas, Ruth Chapman, Desmond Dillon-Murphy, Maria Tort, Vincenza Snow, Erica Chilson, Raymond Farkouh","doi":"10.1080/13696998.2024.2339638","DOIUrl":"https://doi.org/10.1080/13696998.2024.2339638","url":null,"abstract":"The US Food and Drug Administration approved the 20-valent pneumococcal conjugate vaccine (PCV20) to prevent pneumococcal disease. In the context of routine PCV20 vaccination, we evaluated the cost...","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":"92 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140564599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Economic impact analysis of a minimally invasive temperature-controlled radiofrequency device versus nasal surgery for the treatment of nasal airway obstruction in the United States","authors":"Michael Yong, Desiree Hollemon, Julie Baxter, Alex Hirst, Sam Bryning, Aimee Fox, Greg Smith, Robert Hughes, Giulia Brandolini, Scott Wolf, Randall Ow","doi":"10.1080/13696998.2024.2340385","DOIUrl":"https://doi.org/10.1080/13696998.2024.2340385","url":null,"abstract":"Objective: To determine the economic impact of a minimally invasive temperature-controlled radiofrequency (TCRF) device for treating nasal airway obstruction (NAO).Methods: A budget impact model wa...","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":"82 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140564764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global burden and economic impact of vaccine-preventable cancer mortality.","authors":"Goran Bencina, Edward Oliver, Anne Meiwald, Robert Hughes, Edith Morais, Georgie Weston, Karin Sundström","doi":"10.1080/13696998.2024.2350877","DOIUrl":"10.1080/13696998.2024.2350877","url":null,"abstract":"<p><strong>Background: </strong>Infections are responsible for approximately 13% of cancer cases worldwide and many of these infections can be prevented by vaccination. Human papillomavirus (HPV) and hepatitis B virus (HBV) are among the most common infections that cause cancer deaths globally, despite effective prophylactic vaccines being available. This analysis aims to estimate the global burden and economic impact of vaccine-preventable cancer mortality across World Health Organization (WHO) regions.</p><p><strong>Methods: </strong>The number of deaths and years of life lost (YLL) due to five different vaccine-preventable cancer forms (oral cavity, liver, laryngeal, cervical, and oropharyngeal cancer) in each of the WHO regions (African, Eastern Mediterranean, European, the Americas, South-East Asia Pacific, and Western Pacific) were obtained from the Institute for Health Metrics Evaluation global burden of disease dataset. Vaccine-preventable mortality was estimated considering the fraction attributable to infection, to estimate the number of deaths and YLL potentially preventable through vaccination. Data from the World Bank on GDP per capita were used to estimate the value of YLL (VYLL). The robustness of these results was explored with sensitivity analysis. Given that several Epstein-Barr virus (EBV) vaccines are in development, but not yet available, the impact of a potential vaccine for EBV was evaluated in a scenario analysis.</p><p><strong>Results: </strong>In 2019, there were 465,740 potentially vaccine-preventable cancer deaths and 14,171,397 YLL across all WHO regions. The estimated economic impact due to this mortality was $106.3 billion globally. The sensitivity analysis calculated a range of 403,025-582,773 deaths and a range in productivity cost of $78.8-129.0 billion. In the scenario analysis EBV-related cancer mortality increased the global burden by 159,723 deaths and $32.4 billion.</p><p><strong>Conclusion: </strong>Overall, the findings from this analysis illustrate the high economic impact of premature cancer mortality that could be potentially preventable by vaccination which may assist decision-makers in allocating limited resources among competing priorities. Improved implementation and increased vaccination coverage of HPV and HBV should be prioritized to decrease this burden.</p>","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":" ","pages":"9-19"},"PeriodicalIF":2.4,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140891709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The indirect costs and burden of vaccine-preventable cancers premature mortality in Asia-Pacific countries.","authors":"Goran Bencina, Manoj Gambhir, Isaya Sukarom, Athar Hasan Siddiqui, Edward Oliver, Anne Meiwald, Robert Hughes, Amanda Eiden, Georgie Weston","doi":"10.1080/13696998.2025.2468120","DOIUrl":"10.1080/13696998.2025.2468120","url":null,"abstract":"<p><strong>Background: </strong>Cancer is the second leading cause of death in the Asia-Pacific region. Human papillomavirus (HPV) and hepatitis B virus (HBV) are major cancer-causing infections. This analysis assessed the mortality impact and productivity losses due to HBV- and HPV-related cancers in ten Asia-Pacific countries.</p><p><strong>Methods: </strong>Number of deaths and years of life lost (YLL) in 2019 were sourced from the Institute for Health Metrics Evaluation Global Burden of Disease for the following: HBV-related liver cancer, and HPV-related oral cavity, larynx, oropharynx, and cervical cancers (other HPV-related cancers were not included). Ten countries from the Asia-Pacific region were included. Attributable fractions of HPV-related cancers were applied. Average YLL (AYLL) was calculated as the average number of years a person would have lived if they had not died prematurely. The value of YLL (VYLL) was estimated using GDP per capita and YLL. Discount rate of 3% was applied to adjust future health losses to present value. Sensitivity and scenario analyses were also conducted to assess the robustness of the results.</p><p><strong>Results: </strong>In 2019, 52,796 deaths and 1,493,438 YLL were caused by HBV- and HPV-related cancer in the selected Asia-Pacific countries, incurring a productivity loss of $15 billion. Liver cancer accounted for 62.2% of the total productivity loss followed by cervical cancer (35.5%). The Asia-Pacific region had an AYLL of 28, with values ranging from 21 (Japan) to 34 (Philippines). Republic of Korea had the highest productivity losses followed by Japan and Thailand ($5.6, $4.3 and $1.8 billion, respectively).</p><p><strong>Conclusion: </strong>The Asia-Pacific region bears a significant economic burden from potentially vaccine-preventable cancers. Enhanced public health measures, including screening and expanded HBV and HPV vaccination coverage, could alleviate this burden.</p>","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":" ","pages":"51-61"},"PeriodicalIF":2.9,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Burden and indirect cost of vaccine-preventable cancer mortality in Europe.","authors":"Goran Bencina, Ugne Sabale, Edith Morais, Olga Ovcinnikova, Edward Oliver, Hayley Shoel, Anne Meiwald, Robert Hughes, Georgie Weston, Karin Sundström","doi":"10.1080/13696998.2024.2374684","DOIUrl":"https://doi.org/10.1080/13696998.2024.2374684","url":null,"abstract":"<p><strong>Background: </strong>The economic and mortality burden of cancer is high worldwide. In Europe, cancer was responsible for 1.3 million deaths in 2020 and incurred an estimated cost of €50 billion from premature mortality. Human papillomavirus (HPV) and hepatitis B virus (HBV) are among the leading causes of infection-related cancers despite the availability of effective vaccines against these infections. This analysis estimated the mortality and productivity loss of HBV- and HPV-associated cancers that could be preventable through vaccination across European regions.</p><p><strong>Materials and methods: </strong>Institute for Health Metrics Evaluation (IHME) data were used to estimate mortality, years of life lost (YLL), and the value of years of life lost (VYLL) from five HBV- and HPV-related cancers (oral cavity, oropharynx, larynx, cervical, and liver cancers) across 40 European countries in 2019. Preventable deaths and YLL were estimated based on fractions attributable to infections. Data from the World Bank on GDP per capita were used to estimate the VYLL. The robustness of these results was explored with sensitivity and scenario analyses.</p><p><strong>Results: </strong>In 2019, 31,906 cancer deaths resulted in an economic burden of €18,521,614,725 due to productivity losses across Europe. HPV-related cervical cancer had the highest mortality (19,473 deaths) and economic burden (€10,706,253,185). HBV-related liver cancer and HPV-related larynx, oral cavity, and oropharynx cancers also had a substantial burden, particularly in males. Eastern Europe had the highest YLL (308,179; 39%) and Western Europe was responsible for the greatest VYLL (€8,281,306,504; 45%), although the highest VYLL per death was in Northern Europe (€923,638). HPV-related oropharynx cancer had the highest VYLL per death (€656,607).</p><p><strong>Conclusion: </strong>HPV- and HBV-related cancer deaths are associated with substantial mortality and productivity losses in Europe, which could be reduced by the continued prioritization and implementation of prophylactic public health measures including systematic awareness, vaccination, and screening efforts.</p>","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":"27 sup2","pages":"30-40"},"PeriodicalIF":2.9,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141620183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Productivity costs due to human papillomavirus-related cancer mortality in the United Kingdom.","authors":"Kayla Engelbrecht, Olga Ovcinnikova, Dionysios Ntais, Hayley Shoel, Anne Meiwald, Robert Hughes, Georgie Weston, Edith Morais, Goran Bencina","doi":"10.1080/13696998.2024.2368986","DOIUrl":"10.1080/13696998.2024.2368986","url":null,"abstract":"<p><strong>Background: </strong>Human papillomavirus (HPV) causes several cancers such as cervical cancer and some head and neck (oral cavity, pharynx, and larynx), vulval, vaginal, anal, and penile cancers. As HPV vaccination is available, there is potential to prevent these cancers attributed to HPV and consequently the burden associated with them. The aim of this analysis was to estimate the number of HPV-related cancer deaths and the productivity costs due to years of life lost (YLL) in the United Kingdom (UK).</p><p><strong>Method: </strong>A model was developed utilizing UK 2019 mortality data sourced from country-specific databases for England, Scotland, Wales, and Northern Ireland for the following HPV-related cancers: head and neck (ICD-10 C00-14 and C32), cervix uteri (C53), vaginal (C51), vulval (C52), anal (C21), and penile (C60). The proportion of deaths and years of life lost (YLL) due to HPV were estimated using HPV attributable fractions for each anatomic location from the published literature. Labor force participation, retirement ages, and mean annual earnings, discounted at 3.5% annually, were applied to YLL to calculate the present value of future lost productivity (PVFLP).</p><p><strong>Results: </strong>A total of 1817 deaths due to HPV-related cancers were reported in the UK in 2019 resulting in 31,804 YLL. Restricting to only YLL that occurred prior to retirement age yielded a total YPLL of 11,765 and a total PVFLP of £187,764,978.</p><p><strong>Conclusions: </strong>There is a high disease burden in the UK for HPV-related cancers, with a large economic impact on the wider economy due to productivity losses. Implementing and reinforcing public health measures to maintain high HPV vaccination coverage in both males and females may further facilitate reduction of this burden.</p>","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":" ","pages":"20-29"},"PeriodicalIF":2.9,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141419467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges, considerations, and approaches for developing a cost-effectiveness model for the adjuvant treatment of muscle-invasive urothelial carcinoma: with a spotlight on nivolumab versus placebo","authors":"Siguroli Teitsson, Thor-Henrik Brodtkorb, Murat Kurt, Miraj Y. Patel, Tayla Poretta, Christopher Knight, Farzam Kamgar, Stephen Palmer","doi":"10.1080/13696998.2024.2322394","DOIUrl":"https://doi.org/10.1080/13696998.2024.2322394","url":null,"abstract":"To present challenges and considerations for the development of a decision analytic model for evaluating the cost-effectiveness of adjuvant nivolumab compared with surveillance in patients with hig...","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":"1 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139924824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction.","authors":"","doi":"10.1080/13696998.2024.2304418","DOIUrl":"https://doi.org/10.1080/13696998.2024.2304418","url":null,"abstract":"","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":"27 1","pages":"153"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139403216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world economic burden of metastatic castration-resistant prostate cancer before and after first-line therapy initiation.","authors":"Deborah R Kaye, Ibrahim Khilfeh, Erik Muser, Laura Morrison, Frederic Kinkead, Ana Urosevic, Patrick Lefebvre, Dominic Pilon, Daniel J George","doi":"10.1080/13696998.2024.2303890","DOIUrl":"10.1080/13696998.2024.2303890","url":null,"abstract":"<p><strong>Aims: </strong>To describe healthcare costs of patients with metastatic castration-resistant prostate cancer (mCRPC) initiating first-line (1 L) therapies from a US payer perspective.</p><p><strong>Methods: </strong>Patients initiating a Flatiron oncologist-defined 1 L mCRPC therapy (index date) on or after mCRPC diagnosis were identified from linked electronic medical records/claims data from the Flatiron Metastatic Prostate Cancer (PC) Core Registry and Komodo's Healthcare Map. Patients were excluded if they initiated a clinical trial drug in 1 L, had <12 months of insurance eligibility prior to index, or no claims in Komodo's Healthcare Map for the Flatiron oncologist-defined index therapy. All-cause and PC-related total costs per-patient-per-month (PPPM), including costs for services and procedures from medical claims (i.e. medical costs) and costs from pharmacy claims (i.e. pharmacy costs), were described in the 12-month baseline period before 1 L therapy initiation (including the baseline pre- and post- mCRPC progression periods) and during 1 L therapy (follow-up).</p><p><strong>Results: </strong>Among 459 patients with mCRPC (mean age 70 years, 57% White, 16% Black, 45% commercially-insured, 43% Medicare Advantage-insured, and 12% Medicaid-insured), average baseline all-cause total costs (PPPM) were $4,576 ($4,166 pre-mCRPC progression, $8,278 post-mCRPC progression). Average baseline PC-related total costs were $2,935 ($2,537 pre-mCRPC progression, $6,661 post-mCRPC progression). During an average 1 L duration of 8.5 months, mean total costs were $13,746 (all-cause) and $12,061 (PC-related) PPPM. The cost increase following 1 L therapy initiation was driven by higher PC-related outpatient and pharmacy costs. PC-related medical costs PPPM increased from $1,504 during baseline to $5,585 following 1 L mCRPC therapy initiation.</p><p><strong>Limitations: </strong>All analyses were descriptive; statistical testing was not performed.</p><p><strong>Conclusion: </strong>Incremental costs of progression to mCRPC are significant, with the majority of costs driven by higher PC-related costs. Using contemporary data, this study highlights the importance of utilizing effective therapies that slow progression and reduce healthcare resource demands despite the initial investment in treatment costs.</p>","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":" ","pages":"201-214"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139417333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}